Cerebrolysin

Overview

Cerebrolysin is a unique pharmaceutical preparation consisting of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain proteins. Developed by the Austrian pharmaceutical company EVER Neuro Pharma (formerly Ebewe Pharma), it has been used clinically for over 40 years in more than 40 countries across Europe, Asia, and Latin America.

Unlike single-peptide therapies, Cerebrolysin is a complex biological mixture containing approximately 25% low-molecular-weight peptides (below 10 kDa) and 75% free amino acids. The peptide fraction is believed to mimic the activity of naturally occurring neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).

Key Characteristics

• Origin: Enzymatic breakdown of purified porcine brain proteins
• Classification: Neurotrophic peptide mixture / Multimodal neuroprotective agent
• Composition: ~25% bioactive peptides, ~75% free amino acids
• Unique Feature: Mimics the activity of multiple endogenous neurotrophic factors simultaneously
• Clinical History: Over 40 years of clinical use in Europe and Asia

Clinical Approvals

Cerebrolysin has received regulatory approval in numerous countries for:

• Alzheimer's disease and vascular dementia
• Acute ischemic stroke
• Traumatic brain injury (TBI)
• Cognitive impairment of various etiologies

Mechanism

Cerebrolysin exerts its effects through multiple neurotrophic and neuroprotective pathways, acting as a multimodal agent on the central nervous system.

Primary Mechanisms

1. Neurotrophic Factor Mimicry

Cerebrolysin's peptide components reproduce the effects of endogenous neurotrophic factors:

• BDNF-like activity: Promotes neuronal survival, differentiation, and synaptic plasticity
• NGF-like activity: Supports cholinergic neuron survival and function
• GDNF-like activity: Protects dopaminergic neurons
• CNTF-like activity: Supports motor neuron and oligodendrocyte survival

2. Anti-Apoptotic Protection

Cerebrolysin activates key survival signaling pathways:

• Upregulates PI3K/Akt pathway, promoting cell survival
• Inhibits caspase-3 and caspase-9 activation
• Reduces pro-apoptotic protein (Bax) expression
• Increases anti-apoptotic protein (Bcl-2) expression

3. Neuroplasticity Enhancement

The peptide mixture promotes structural and functional brain plasticity:

• Enhances dendritic branching and synaptogenesis
• Increases long-term potentiation (LTP) in hippocampus
• Promotes neurogenesis in the subventricular zone and hippocampal dentate gyrus
• Modulates synaptic protein expression

4. Anti-Inflammatory Neuroprotection

Cerebrolysin reduces neuroinflammatory damage:

• Inhibits microglial activation in injury models
• Reduces inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6)
• Attenuates oxidative stress through antioxidant pathway activation
• Protects blood-brain barrier integrity

Cellular Effects

At the cellular level, Cerebrolysin:

• Enhances mitochondrial function and bioenergetics
• Improves calcium homeostasis in stressed neurons
• Promotes oligodendrocyte survival and myelination
• Reduces excitotoxic damage from glutamate overflow
• Modulates amyloid precursor protein (APP) processing

Research

Alzheimer's Disease

Cognitive Improvement

Multiple randomized controlled trials have assessed Cerebrolysin in Alzheimer's disease:

• The CERAD-Plus study (2011) demonstrated significant improvement on ADAS-cog scores compared to placebo after 24 weeks of treatment
• A meta-analysis of 6 double-blind trials showed consistent cognitive benefits at doses of 30 mL/day for 4-week cycles
• EEG studies show improved cortical activity patterns after treatment
• Some evidence of sustained benefit up to 6 months after treatment cessation

Biomarker Effects

• Modulates CSF biomarkers including phospho-tau and amyloid-beta ratios
• Functional neuroimaging shows improved cerebral glucose metabolism
• Reduces hippocampal atrophy progression in some studies

Stroke Recovery

Acute Ischemic Stroke

Cerebrolysin has been extensively studied in stroke:

• The CASTA trial (Cerebrolysin and Recovery After Stroke) enrolled over 1,000 patients
• E-COMPASS study (2018) showed improved motor recovery when combined with rehabilitation
• Evidence supports early administration (within 24-72 hours) for optimal benefit
• Improvements observed in National Institutes of Health Stroke Scale (NIHSS) scores

Mechanism in Stroke

• Reduces infarct volume in animal models by 40-60%
• Protects penumbral neurons from secondary damage
• Promotes neurogenesis and angiogenesis in peri-infarct regions
• Enhances neuroplasticity during rehabilitation

Traumatic Brain Injury

Research in TBI has shown:

• Improved Glasgow Outcome Scale scores in moderate-to-severe TBI
• CAPTAIN trial (2016) showed trends toward improved cognitive outcomes
• Animal studies demonstrate reduced brain edema and contusion volume
• Neuroprotective effects when administered within hours of injury

Pediatric Applications

Limited but promising research in:

• Neonatal hypoxic-ischemic encephalopathy
• Developmental delays
• Cerebral palsy-associated cognitive deficits

Dosing

Clinical Protocols

Administration Notes

Intravenous Administration

• Preferred route for higher doses (>5 mL)
• Dilute in 100-250 mL of normal saline (0.9% NaCl)
• Infuse over 15-60 minutes
• Do not mix with balanced amino acid infusion solutions

Intramuscular Administration

• Suitable for doses up to 5 mL per injection site
• No dilution needed for IM use
• Rotate injection sites
• Typically used for lower-dose protocols

Cycle Structure

Clinical use follows a cyclical pattern:

• Active treatment: 10-20 consecutive days
• Rest period: 4-8 weeks
• Repeat cycles: 2-4 times per year
• Chronic conditions (Alzheimer's) may use ongoing quarterly cycles

Reconstitution

Cerebrolysin is supplied as a ready-to-use amber solution in glass ampoules:

• Available in 1 mL, 5 mL, 10 mL, and 30 mL ampoules
• No reconstitution required
• Inspect visually before use; solution should be clear, amber-colored
• Do not use if turbid or contains particulates

Pharmacokinetics

Absorption

• Intravenous: 100% bioavailability, immediate systemic distribution
• Intramuscular: Approximately 85% bioavailability, gradual absorption from injection site

Distribution

• Crosses the blood-brain barrier due to low molecular weight of peptide components
• Brain penetration confirmed by radiolabeled studies in animal models
• Achieves therapeutic CNS concentrations within 30-60 minutes of IV administration
• Wide distribution throughout cortical and subcortical structures

Metabolism

• Metabolized by ubiquitous peptidases
• Amino acid components enter normal amino acid metabolism pools
• No known CYP450 interactions
• No active metabolites identified beyond constituent amino acids

Elimination

• Half-life: Variable due to mixture composition; peptide fractions have short half-lives (minutes to hours)
• Amino acid components eliminated via normal metabolic pathways
• No accumulation observed with repeated daily dosing
• Renal excretion of amino acid metabolites

Synergy & Stacking

Cerebrolysin can be combined with other therapeutic approaches for enhanced neurological outcomes.

Common Combinations

Cerebrolysin + Physical Rehabilitation

The most well-studied combination:

• Cerebrolysin enhances neuroplasticity during rehabilitation
• Motor learning and recovery significantly improved
• E-COMPASS study validated this combination for stroke recovery

Cerebrolysin + Cholinesterase Inhibitors

For Alzheimer's disease:

• Cerebrolysin provides neurotrophic support
• Cholinesterase inhibitors (donepezil, rivastigmine) enhance synaptic acetylcholine
• Complementary mechanisms may provide additive cognitive benefits
• Some studies show enhanced response when combined

Cerebrolysin + Semax

For cognitive optimization:

• Cerebrolysin delivers broad neurotrophic factor mimicry via IV/IM
• Semax provides targeted BDNF upregulation via intranasal route
• Different administration routes reduce competition
• Complementary mechanisms of neuroprotection

Timing Considerations

• Administer Cerebrolysin in the morning for optimal neurotrophic effect
• Allow IV infusion to complete before other medications
• When combined with rehabilitation, administer 1-2 hours before therapy session
• No significant food interactions

Safety

Known Side Effects

Cerebrolysin has a generally well-tolerated safety profile across decades of clinical use:

Common (1-10%)

• Injection site reactions (pain, redness)
• Dizziness or vertigo
• Headache
• Mild nausea
• Feeling of warmth during infusion

Uncommon (0.1-1%)

• Insomnia or agitation
• Confusion (more common in elderly)
• Mild allergic reactions (skin rash)
• Appetite changes
• Mild fever

Rare (less than 0.1%)

• Seizures (primarily in patients with seizure history)
• Anaphylactic reactions
• Severe allergic reactions

Contraindications

Avoid or use with extreme caution if:

• History of epilepsy or seizure disorders
• Severe renal impairment (eGFR below 30 mL/min)
• Known allergy to porcine-derived products
• Pregnancy or breastfeeding
• Hypersensitivity to any component

Drug Interactions

Limited clinically significant interactions documented, but exercise caution with:

• MAO inhibitors (theoretical monoamine pathway overlap)
• Antiepileptic drugs (seizure threshold effects)
• High-dose lithium (unpredictable CNS effects)

Long-Term Safety

• Decades of post-marketing surveillance in approved countries
• No evidence of prion disease transmission (manufacturing process eliminates risk)
• No carcinogenicity signals in long-term observational data
• No significant immunogenicity reported

Monitoring

Baseline Assessments

Before initiating Cerebrolysin therapy:

• Complete neurological examination
• Cognitive testing (MMSE, MoCA, or ADAS-cog)
• Renal function (serum creatinine, eGFR)
• EEG if seizure history is present
• Brain imaging (MRI) for baseline comparison

During Treatment

• Monitor for injection site reactions (IV and IM)
• Assess neurological status daily during infusion cycles
• Track cognitive function with standardized scales
• Monitor for seizure activity, especially in at-risk patients

Post-Cycle

• Repeat cognitive assessments at cycle completion
• Compare outcomes to baseline
• Renal function check after each cycle
• Plan timing of subsequent treatment cycles

Regulatory

Current Status

Clinical Context

• Manufactured by EVER Neuro Pharma (Austria)
• Over 40 years of clinical use globally
• Part of national stroke treatment guidelines in several countries
• FDA has not approved due to insufficient US-based Phase III trials
• Over 200 publications in peer-reviewed journals

Quality Considerations

• Manufactured under GMP standards in Austria
• Standardized purification and quality control processes
• Each batch tested for biological activity
• Prion risk eliminated through validated manufacturing processes

References